Article
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Investigational new drugs - 1 Aug 2013
Yan S Betty, Peek Victoria L, Ajamie Rose, Buchanan Sean G, Graff Jeremy R, Heidler Steven A, Hui Yu-Hua, Huss Karen L, Konicek Bruce W, Manro Jason R, Shih Chuan, Stewart Julie A, Stewart Trent R, Stout Stephanie L, Uhlik Mark T, Um Suzane L, Wang Yong, Wu Wenjuan, Yan Lei, Yang Wei J, Zhong Boyu, Walgren Richard A
Abstract excerpt
The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis. MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand production, and missense MET mutations are mechanisms that lead to activation of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.